|
|
|
Orthofix Medical Inc (NASDAQ: OFIX) |
|
|
|
| |
Orthofix Medical Inc Outlook |
On November 8 2024 the Orthofix Medical Inc provided following guidance
nnOrthofix Medical Inc. Announces Third Quarter 2024 Results and Updates Financial Projectionsnn
nnLEWISVILLE, Texasnn - Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in global medical technology, has unveiled its financial outcomes for the third quarter ending September 30, 2024. The company has reaffirmed its financial guidance for the entire year and introduced new financial targets for the next three years.
### Key Highlights
In the third quarter of 2024, Orthofix reported net sales of $196.6 million, reflecting a robust increase of 7% when compared to the same period in 2023, whether assessed on a reported basis or in constant currency terms. Notably, the growth in U.S. Spine Fixation segment sales has played a critical role in this uptrend.
### Financial Guidance and Future Targets
Alongside the quarterly results, Orthofix is maintaining its financial outlook for the year 2024. The company has also laid out ambitious financial targets for the upcoming three years, signaling their commitment to continued growth and innovation in the medical technology sector. While specific numerical targets and detailed financial figures were not disclosed in this announcement, Orthofix's management remains optimistic about achieving these new benchmarks.
Orthofix’s focus on expanding its product offerings and enhancing operational efficiency is expected to contribute positively to its financial performance moving forward.
In summary, Orthofix Medical Inc. has made significant strides in its third-quarter performance while also reinforcing its commitment to long-term growth through new financial targets and sustained financial guidance for 2024.,
|
On August 6 2024 the Orthofix Medical Inc provided following guidance
nnOrthofix Medical Inc. Elevates Full-Year 2024 Financial Outlook Following Strong Q2 Performancenn
On August 6, 2024, Orthofix Medical Inc. (NASDAQ: OFIX), headquartered in Lewisville, Texas, disclosed its financial performance for the second quarter ending June 30, 2024, alongside an upward revision of its financial projections for the entire year.
### Key Highlights from Q2 2024
- nnImpressive Revenue Figuresnn: During the second quarter, Orthofix achieved net sales amounting to $198.6 million. This represents a 6% increase compared to the same period in 2023, both on a reported basis and when adjusted for currency fluctuations.
- nnGrowth in Bone Growth Therapiesnn: Notably, the company observed a 12% increase in sales from its Bone Growth Therapies (BGT) segment when compared to the second quarter of the previous year. This marks a significant achievement, as Orthofix has now experienced six consecutive quarters of double-digit sales growth within this category.
### Increased Financial Guidance for 2024
In light of these robust quarterly results, Orthofix has opted to revise its financial guidance for the full year of 2024. The updated outlook reflects the company’s strong market performance and confidence in sustaining this momentum. While specific numerical details regarding the revised guidance were not disclosed in the announcement, the overall sentiment suggests a positive trajectory for the remainder of the year.
As Orthofix Medical continues to leverage its strengths in the medical device industry, investors and stakeholders will be keenly monitoring developments that may arise from this encouraging financial performance.
|
On March 5 2024 the Orthofix Medical Inc provided following guidance
Orthofix Medical Inc., a leading medical device company, has released its financial results for the fourth quarter and full year of 2023. The company reported strong fourth quarter net sales of $200.4 million, reflecting a significant increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Despite this positive sales growth, the company also reported a net loss of $(22.2) million and earnings per share of $(0.59) on a reported basis. However, this represents an improvement of 19% when compared to pro forma results.
Looking ahead to 2024, Orthofix Medical Inc. has provided guidance for the full year. The company is optimistic about its future prospects and expects to continue its growth trajectory. With a strong focus on innovation and market expansion, Orthofix is confident in its ability to deliver long-term value for its shareholders.
Overall, the company's performance in 2023 demonstrates its resilience and ability to adapt to changing market conditions. With a solid foundation and strategic focus on growth, Orthofix Medical Inc. is well-positioned to achieve success in the coming year and beyond.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
